External validation of the modified Glasgow prognostic score for renal cancer

Indian Journal of Urology

Volumn 30, Issue 1, 2014, Pages 33-37

  Tai, Caroline G ^a   Johnson, Timothy V ^a   Abbasi, Ammara ^a   Herrell, Lindsey ^a   Harris, Wayne B ^a   Kucuk, Omer ^b   Canter, Daniel J ^a   Ogan, Kenneth ^a   Pattaras, John G ^a   Nieh, Peter T ^a   Master, Viraj A ^a  

^a Department of Urology 1365 Clifton Road NE ^*  (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Albumin; biological markers; C reactive protein; metastasis; renal cell carcinoma

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL VALIDITY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MODIFIED GLASGOW PROGNOSTIC SCORE; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COUNSELING; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SCORING SYSTEM; VALIDATION STUDY;

EID: 84929354973     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.124203     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-Age and stage characterization and clinical implications: Study of 1092 patients (1982-1997). Urology 2000;56:58-62.
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843-52.
4. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: New frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005;173:1853-62.
5. Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: The TNM-C score. J Urol 2009;181:1004-12.
6. Ljungberg B. Prognostic markers in renal cell carcinoma. Curr Opin Urol 2007;17:303-8.
7. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: A European study of 313 patients. Cancer 2007;110:1241-7.
8. Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, et al. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int 2008;102:756-61.
9. Johnson TV, Young AN, Osunkoya AO, Master VA. C-reactive protein as a clinically useful biomarker of metastasis of renal cell carcinoma. Mol Diagn Ther 2010;14:191-3.
10. Jabs WJ, Busse M, Krüger S, Jocham D, Steinhoff J, Doehn C. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int 2005;68:2103-10.
11. Canna K, McMillan DC, McKee RF, McNicol AM, Horgan PG, McArdle CS. Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer 2004;90:1707-9.
12. McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer 2004;91:1993-5.
13. Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 2007;99:77-80.
14. Johnson TV, Abbasi A, Owen-Smith A, Young A, Ogan K, Pattaras J, et al. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. J Urol 2010;183:480-5.
15. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003;89:1028-30.
16. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004;90:1704-6.
17. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 2006;94:227-30.
18. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer 2006;94:637-41.
19. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 2006;6:450-3.
20. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149-63.
21. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007;109:205-12.
22. Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Union internationale contre le cancer and the American joint committee on cancer. Cancer 1997;80:1803-4.
23. Fuhrrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
24. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20:4559-66.
25. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol 2002;168:2395-400.
26. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001;166:63-7.
27. McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS. Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer 1998;31:101-5.
28. Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264-7.
29. Costelli P, Reffo P, Penna F, Autelli R, Bonelli G, Baccino FM. Ca (2+)-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol 2005;37:2134-46.
30. Crotzer VL, Blum JS. Cytosol to lysosome transport of intracellular antigens during immune surveillance. Traffic 2008;9:10-6.
31. Trapani JA, Sutton VR. Granzyme B: Pro-Apoptotic, antiviral and antitumor functions. Curr Opin Immunol 2003;15:533-43.
32. Goldberg AL. Functions of the proteasome: From protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 2007;35:12-7.
33. Faber J, Vos AP, Kegler D, Argilés J, Laviano A, Garssen J, et al. Impaired immune function: An early marker for cancer cachexia. Oncol Rep 2009;22:1403-6.
34. Heikkilä K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007;61:824-33.